HPV Positive Oropharyngeal Squamous Cell Carcinoma Clinical Trial
Official title:
Improving Detection and Early Action for HPV-positive Oropharynx Cancer
This study aims to determine whether a blood test for HPV DNA can improve diagnosis of HPV-positive oropharynx cancer (HPV-OPC).
The diagnosis of HPV-OPC is often delayed. In this study, individuals with signs or symptoms potentially related to HPV-OPC, such as unexplained throat pain, tonsil or tongue base asymmetry, or a neck mass, will have their blood tested for circulating HPV DNA. A positive test may indicate that their symptoms are caused by HPV-OPC, and their treating physician will be encouraged to complete all the necessary testing to determine whether this is the case. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02113878 -
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
| Recruiting |
NCT04444869 -
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
|
Phase 2 | |
| Withdrawn |
NCT04001413 -
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT05524025 -
The SPOT-HPV Study
|
||
| Recruiting |
NCT05600842 -
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
|
||
| Terminated |
NCT05061940 -
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
|
||
| Recruiting |
NCT05119036 -
Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06088381 -
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
|
Phase 2 | |
| Recruiting |
NCT05686226 -
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
|
Phase 2 | |
| Recruiting |
NCT05814549 -
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
|
||
| Active, not recruiting |
NCT04260126 -
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
|
Phase 2 | |
| Recruiting |
NCT05307939 -
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
|
Phase 2 | |
| Not yet recruiting |
NCT06319963 -
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03601507 -
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01855451 -
Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
|
Phase 3 | |
| Terminated |
NCT04301011 -
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05639972 -
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03978689 -
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04900623 -
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
|
Phase 2 | |
| Recruiting |
NCT03215719 -
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma
|
Phase 2 |